Stockscreener 앱 받기
24.25
9.18%
1.372
전일 마감가:
$22.88
열려 있는:
$24
하루 거래량:
7,481
Relative Volume:
0.01
시가총액:
$2.02B
수익:
-
순이익/손실:
$-154.65M
주가수익비율:
-10.20
EPS:
-2.3786
순현금흐름:
$-142.43M
1주 성능:
+7.30%
1개월 성능:
-13.95%
6개월 성능:
-37.53%
1년 성능:
+54.67%
1일 변동 폭
$24.00
$24.51
1주일 범위
$22.42
$24.64
52주 변동 폭
$10.44
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
24.47 | 2.03B | 0 | -154.65M | -142.43M | -2.3786 |
VRTX
Vertex Pharmaceuticals Inc
|
452.50 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
752.21 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.13 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.41 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.84 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 개시 | Jefferies | Hold |
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Mineralys reports 2025 results, advances hypertension drug review - MSN
Mineralys Therapeutics names Jeffrey Munsie as chief legal officer By Investing.com - Investing.com Australia
Biopharma Co. Gives New CLO $3.6 Million In Stock Awards - Law360
Mineralys Therapeutics grants inducement equity awards to two new employees - MSN
Mineralys Therapeutics appoints Jeffrey Munsie as chief legal officer - TipRanks
Mineralys Grants Inducement Equity Awards to New Employee - MyChesCo
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer - citybiz
Mineralys Therapeutics names Jeffrey Munsie as chief legal officer - Investing.com
Mineralys Therapeutics appoints Jeffrey A. Munsie as chief legal officer - marketscreener.com
Mineralys Therapeutics, Inc. Appoints Jeffrey A. Munsie as Chief Legal Officer - marketscreener.com
Mineralys Therapeutics (MLYS) Is Down 8.1% After Narrowed Loss, FDA Lorundrostat NDA AcceptanceWhat's Changed - simplywall.st
Hudson Bay Capital Management LP Invests $2.87 Million in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Earnings Beat: Whats the profit margin of Mineralys Therapeutics IncQuarterly Risk Review & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Growth Value: What is the implied volatility of Mineralys Therapeutics Inc2026 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? - Yahoo Finance
Mineralys (MLYS) Q4 2025 Earnings Call Transcript - AOL.com
Why Mineralys Therapeutics Shares Are Sliding Today - TipRanks
Research Analysts Issue Forecasts for MLYS Q1 Earnings - MarketBeat
Rodman David Malcom sells Mineralys Therapeutics (MLYS) stock for $10,696 - Investing.com Canada
Insider sale notices at Mineralys Therapeutics (NASDAQ: MLYS) detail multiple Q1 2026 transactions - Stock Titan
Mineralys Therapeutics (MLYS) CMO exercises stock options and sells shares - Stock Titan
Mineralys Reports 2025 Results, Advances Hypertension Drug Review - MyChesCo
Risk Check: Will Mineralys Therapeutics Inc outperform tech stocksTrade Volume Report & Growth-Oriented Investment Plans - baoquankhu1.vn
HC Wainwright Has Positive Outlook of MLYS FY2029 Earnings - MarketBeat
Holocene Advisors LP Buys Shares of 1,205,377 Mineralys Therapeutics, Inc. $MLYS - MarketBeat
David Malcom Rodman Sells 14,058 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
David Malcom Rodman Sells 6,348 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Therapeutics MLYS CMO sells shares worth $542,973 By Investing.com - Investing.com Canada
Mineralys Therapeutics CMO Sells Over 20,000 Shares - TradingView
Mineralys targets December 2026 lorundrostat approval as payer engagement and data drive launch strategy - MSN
Mineralys (MLYS) CMO exercises options, sells 20,406 shares under 10b5-1 plan - Stock Titan
Mineralys Therapeutics reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Mineralys hire gets stock options and RSUs vesting over four years - Stock Titan
Mineralys: Advancing Lorundrostat Toward Commercialization in Uncontrolled Hypertension With Differentiated Efficacy and Safety - TipRanks
HighVista Strategies LLC Boosts Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Farallon Capital Management LLC Purchases Shares of 1,673,053 Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Cinctive Capital Management LP Has $2.72 Million Stock Holdings in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Reports Strong Phase 3 Results for Lorundrostat in High-Risk Hypertension Patients - MSN
Boothbay Fund Management LLC Increases Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics, Inc. $MLYS Shares Sold by 22NW LP - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Upgraded to Hold at Wall Street Zen - MarketBeat
Losartan Side Effects You Shouldn’t Ignore—Plus One That May Actually Help - AOL.com
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Suvretta Capital Management LLC - MarketBeat
Integral Health Asset Management LLC Lowers Stake in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics (MLYS) makes progress with FDA for hypertension - MSN
Mineralys Therapeutics Charts Path After NDA Acceptance - TipRanks
Jefferies Maintains MLYS at Hold for Mineralys Therapeutics, Inc. March 2026 - Meyka
David Rodman sells multiple Mineralys (NASDAQ: MLYS) share tranches in Q1 2026 - Stock Titan
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Mineralys Therapeutics Inc 주식 (MLYS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rodman David Malcom | Chief Medical Officer |
Mar 17 '26 |
Option Exercise |
15.44 |
417 |
6,438 |
76,557 |
| Rodman David Malcom | Chief Medical Officer |
Mar 17 '26 |
Sale |
25.65 |
417 |
10,696 |
76,140 |
| Rodman David Malcom | Chief Medical Officer |
Mar 13 '26 |
Option Exercise |
12.39 |
7,709 |
95,508 |
90,198 |
| Rodman David Malcom | Chief Medical Officer |
Mar 12 '26 |
Option Exercise |
1.08 |
6,348 |
6,856 |
88,837 |
| Rodman David Malcom | Chief Medical Officer |
Mar 13 '26 |
Sale |
26.26 |
14,058 |
369,225 |
76,140 |
| Rodman David Malcom | Chief Medical Officer |
Mar 12 '26 |
Sale |
27.37 |
6,348 |
173,748 |
82,489 |
1.13%
3.03%
자본화:
|
볼륨(24시간):